Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors

Description

This study is to evaluate the safety and tolerability of RMC-9805 as monotherapy and in combination with RMC-6236 in adults with KRAS G12D-mutant solid tumors.

Conditions

Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid Tumors

Talk to us

Study Overview

On this page

Study Details

Study overview

This study is to evaluate the safety and tolerability of RMC-9805 as monotherapy and in combination with RMC-6236 in adults with KRAS G12D-mutant solid tumors.

Phase 1/1b, Multicenter, Open-Label, Study of RMC 9805 in Participants With Advanced KRASG 12D-Mutant Solid Tumors

Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors

Condition
Non-small Cell Lung Cancer (NSCLC)
Intervention / Treatment

-

Contacts and Locations

Sacramento

University of California, Davis Comprehensive Cancer Center, Sacramento, California, United States, 95817

New Haven

Smilow Cancer Hospital (Yale University), New Haven, Connecticut, United States, 06511

Sarasota

Florida Cancer Specialists, Sarasota, Florida, United States, 34232

Tampa

Lee Moffitt Cancer Center, Tampa, Florida, United States, 33612

Baltimore

Johns Hopkins University, Baltimore, Maryland, United States, 21287

Boston

Massachusetts General Hospital, Boston, Massachusetts, United States, 02114

Boston

Dana-Farber Cancer Institute, Boston, Massachusetts, United States, 02215

New York

NYU Langone, New York, New York, United States, 10016

New York

Memorial Sloan Kettering Cancer Center, New York, New York, United States, 10065

Durham

Duke Cancer Center, Durham, North Carolina, United States, 27710

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Pathologically documented, locally advanced or metastatic solid tumor with a KRAS G12D-mutation
  • * Received and progressed or been intolerant to prior standard therapy (including targeted therapy) appropriate for tumor type and stage
  • * ECOG performance status 0 or 1
  • * Adequate organ function
  • * Primary central nervous system (CNS) tumors
  • * Known or suspected leptomeningeal or active brain metastases or spinal cord compression
  • * Known or suspected impairment of gastrointestinal function that may prohibit ability to swallow or absorb an oral medication
  • * Participant was previously treated with an investigational KRAS G12D inhibitor, pan- or multi-RAS inhibitor, or had prior therapy with any direct RAS-targeted therapy (eg, degraders and inhibitors)

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Revolution Medicines, Inc.,

Revolution Medicines, Inc., STUDY_DIRECTOR, Revolution Medicines, Inc.

Study Record Dates

2027-04-30